|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 61.12 CNY | -1.32% |
|
-4.28% | +2.60% |
| 01-12 | Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug | MT |
| 01-12 | Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation | MT |
| Capitalization | 407B 58.42B 50.18B 46.56B 43.5B 80.99B 5,309B 87.03B 538B 212B 2,528B 219B 215B 9,237B | P/E ratio 2025 * |
45.8x | P/E ratio 2026 * | 41.7x |
|---|---|---|---|---|---|
| Enterprise value | 368B 52.85B 45.39B 42.12B 39.35B 73.26B 4,802B 78.72B 487B 192B 2,287B 198B 194B 8,356B | EV / Sales 2025 * |
11.1x | EV / Sales 2026 * | 9.78x |
| Free-Float |
52.38% | Yield 2025 * |
0.45% | Yield 2026 * | 0.52% |
| 1 day | -1.32% | ||
| 1 week | -4.28% | ||
| Current month | +2.60% | ||
| 1 month | +0.44% | ||
| 3 months | -6.11% | ||
| 6 months | +4.02% | ||
| Current year | +2.60% |
| 1 week | 60.66 |  | 65.6 |
| 1 month | 59.5 | | 65.83 |
| Current year | 59.99 | | 65.83 |
| 1 year | 43.67 | | 74.04 |
| 3 years | 35.51 | | 74.04 |
| 5 years | 27 | | 94.69 |
| 10 years | 12.9 | | 97.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jian Jun Liu
DFI | Director of Finance/CFO | 49 | 2021-11-18 |
Ji Feng
PSD | President | - | 2025-04-01 |
Yu Xu
CMP | Compliance Officer | 34 | 2021-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Jie Ping Sun
BRD | Director/Board Member | 56 | 2020-01-15 |
Hong Bin Dai
BRD | Director/Board Member | 50 | 2020-01-15 |
Piao Yang Sun
CHM | Chairman | 67 | 2021-07-07 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -19.71% | 4.18% | 0 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.32% | -4.28% | +42.67% | +40.05% | 59.15B | |
| +0.53% | -3.94% | +43.09% | +195.77% | 930B | |
| -0.41% | +4.26% | +48.72% | +28.98% | 527B | |
| -1.11% | -2.59% | +24.94% | +44.14% | 379B | |
| -0.60% | +1.26% | +29.94% | +17.78% | 371B | |
| -1.15% | -1.63% | +26.99% | +21.63% | 292B | |
| -0.03% | +1.51% | +29.51% | +36.74% | 276B | |
| -1.93% | -0.33% | +11.14% | -0.97% | 270B | |
| -2.92% | -0.41% | -31.52% | -21.19% | 268B | |
| +0.12% | +1.50% | +21.43% | +26.10% | 178B | |
| Average | -0.88% | +0.06% | +24.69% | +38.90% | 355.01B | |
| Weighted average by Cap. | -0.58% | +0.37% | +29.07% | +67.08% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 33.1B 4.75B 4.08B 3.79B 3.54B 6.59B 432B 7.08B 43.77B 17.24B 206B 17.83B 17.46B 751B | 36.92B 5.3B 4.55B 4.22B 3.95B 7.35B 482B 7.9B 48.81B 19.23B 229B 19.88B 19.47B 838B |
| Net income | 8.76B 1.26B 1.08B 1B 936M 1.74B 114B 1.87B 11.58B 4.56B 54.41B 4.72B 4.62B 199B | 9.72B 1.4B 1.2B 1.11B 1.04B 1.93B 127B 2.08B 12.85B 5.06B 60.39B 5.23B 5.13B 221B |
| Net Debt | -38.82B -5.57B -4.79B -4.44B -4.15B -7.73B -507B -8.3B -51.33B -20.21B -241B -20.9B -20.48B -881B | -45.64B -6.55B -5.63B -5.22B -4.88B -9.09B -596B -9.76B -60.35B -23.77B -284B -24.58B -24.07B -1,036B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-19 | 61.12 ¥ | -1.32% | 47,389,090 |
| 26-01-16 | 61.94 ¥ | -1.95% | 52,378,620 |
| 26-01-15 | 63.17 ¥ | -0.69% | 46,761,230 |
| 26-01-14 | 63.61 ¥ | -1.41% | 62,925,530 |
| 26-01-13 | 64.52 ¥ | +1.05% | 74,034,030 |
End-of-day quote Shanghai S.E., January 18, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 600276 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition